Currently, patients with diabetic erectile dysfunction (DMED) were not satisfied with the effects of first‐line phosphodiesterase type 5 inhibitors (PDE5Is). Hence, this paper was designed to mine hub biomarkers in… Click to show full abstract
Currently, patients with diabetic erectile dysfunction (DMED) were not satisfied with the effects of first‐line phosphodiesterase type 5 inhibitors (PDE5Is). Hence, this paper was designed to mine hub biomarkers in DMED and explore its potential mechanisms.
               
Click one of the above tabs to view related content.